ketoconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 1527 65277-42-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketoconazole
  • (+/-)-ketoconazole
  • brizoral
  • fungarest
  • fungoral
  • ketoderm
  • ketoisdin
  • ketozoral
  • nizoral
  • nizral
  • panfungol
  • ketoconazol
  • R-41400
Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.
  • Molecular weight: 531.43
  • Formula: C26H28Cl2N4O4
  • CLOGP: 3.44
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 0
  • TPSA: 69.06
  • ALOGS: -4.76
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g V
0.60 g O
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 10.75 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,STK33,TEK,TGFBR1 32
kinase-selectivity-class AXL,ERBB2,GRK2,SIK2 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 4.236 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
rat-kpuu-brain Rat brain Kpuu 0.040 % High 1

Approvals:

DateAgencyCompanyOrphan
June 12, 1981 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 205.68 13.10 191 16862 147563 90463831
Dermatitis atopic 125.20 13.10 69 16984 23403 90587991
Skin exfoliation 112.60 13.10 97 16956 67816 90543578
Drug ineffective 107.70 13.10 528 16525 1383770 89227624
Seborrhoeic dermatitis 101.72 13.10 29 17024 1691 90609703
Product use in unapproved indication 91.70 13.10 198 16855 336038 90275356
Dry skin 91.16 13.10 97 16956 87976 90523418
Papule 89.47 13.10 39 17014 7963 90603431
Pruritus 77.83 13.10 251 16802 541274 90070120
Endocrine ophthalmopathy 67.54 13.10 19 17034 1055 90610339
Toxic shock syndrome 63.53 13.10 18 17035 1026 90610368
Eyelid disorder 61.86 13.10 21 17032 2182 90609212
Drug ineffective for unapproved indication 61.29 13.10 69 16984 66575 90544819
Swelling of eyelid 59.08 13.10 26 17027 5428 90605966
Nasal ulcer 57.94 13.10 21 17032 2645 90608749
Product dose omission issue 55.96 13.10 150 16903 291537 90319857
Glossodynia 45.77 13.10 4 17049 321775 90289619
Dermatitis 45.72 13.10 36 17017 22184 90589210
Infusion related reaction 44.03 13.10 12 17041 416768 90194626
Mean cell haemoglobin increased 43.54 13.10 19 17034 3886 90607508
Pustule 42.11 13.10 17 17036 2866 90608528
Cortisol increased 41.34 13.10 11 17042 495 90610899
Systemic lupus erythematosus 40.99 13.10 9 17044 361887 90249507
Xerosis 40.84 13.10 14 17039 1497 90609897
Adrenal insufficiency 40.22 13.10 38 17015 29883 90581511
Skin plaque 39.05 13.10 24 17029 9951 90601443
Wound 37.58 13.10 6 17047 302974 90308420
Eczema 35.97 13.10 47 17006 52823 90558571
Hypothalamic pituitary adrenal axis suppression 35.64 13.10 9 17044 329 90611065
Skin disorder 35.45 13.10 39 17014 36667 90574727
Tarsal tunnel syndrome 35.34 13.10 10 17043 567 90610827
Purpura senile 34.71 13.10 10 17043 605 90610789
Skin burning sensation 34.50 13.10 29 17024 19582 90591812
Hepatic enzyme increased 33.48 13.10 13 17040 360723 90250671
Contraindicated product administered 32.36 13.10 10 17043 320129 90291265
Intertrigo 31.87 13.10 10 17043 810 90610584
Dyslipidaemia 31.35 13.10 21 17032 10086 90601308
Rash 30.24 13.10 254 16799 795846 89815548
Aspergillus test positive 29.21 13.10 8 17045 402 90610992
Abortion spontaneous 29.19 13.10 43 17010 54013 90557381
Eye infection 29.12 13.10 23 17030 14231 90597163
Lower respiratory tract infection 28.84 13.10 6 17047 250653 90360741
Acne 28.77 13.10 31 17022 28476 90582918
Folliculitis 27.84 13.10 3 17050 204350 90407044
Injection site pain 27.11 13.10 83 16970 173616 90437778
Synovial cyst 26.26 13.10 20 17033 11732 90599662
Vestibular disorder 25.65 13.10 10 17043 1539 90609855
Impetigo 25.54 13.10 10 17043 1556 90609838
Product administration interrupted 25.18 13.10 20 17033 12472 90598922
Seborrhoeic keratosis 24.58 13.10 12 17041 3168 90608226
Resorption bone increased 24.26 13.10 9 17044 1210 90610184
Impaired healing 24.23 13.10 7 17046 234192 90377202
Vertigo positional 24.01 13.10 12 17041 3332 90608062
General physical health deterioration 23.99 13.10 19 17034 355096 90256298
Vitamin D decreased 23.77 13.10 19 17034 11960 90599434
Skin ulcer 23.06 13.10 37 17016 50038 90561356
Therapeutic product effect incomplete 22.60 13.10 84 16969 193812 90417582
Skin laceration 22.31 13.10 26 17027 26009 90585385
Pneumonia mycoplasmal 22.02 13.10 8 17045 1014 90610380
Mobility decreased 21.71 13.10 10 17043 250724 90360670
Pelvic pain 21.59 13.10 20 17033 15337 90596057
Feeding disorder 21.20 13.10 21 17032 17491 90593903
Flatulence 21.04 13.10 32 17021 41335 90570059
Tinea capitis 20.82 13.10 4 17049 39 90611355
Skin lesion 20.57 13.10 30 17023 37335 90574059
Surgery 20.44 13.10 33 17020 44854 90566540
Skin fissures 19.90 13.10 22 17031 20787 90590607
Drug interaction 19.46 13.10 103 16950 276350 90335044
Hyperadrenocorticism 19.15 13.10 6 17047 484 90610910
Swelling 18.98 13.10 31 17022 419027 90192367
Synovitis 18.35 13.10 21 17032 329731 90281663
Blister 18.04 13.10 13 17040 254985 90356409
Deafness bilateral 18.02 13.10 8 17045 1705 90609689
Liver injury 17.82 13.10 5 17048 170562 90440832
Otitis media 17.73 13.10 12 17041 5858 90605536
Toxicity to various agents 17.50 13.10 17 17036 287829 90323565
Neoplasm 17.40 13.10 14 17039 8889 90602505
Myalgia 17.27 13.10 72 16981 175053 90436341
Arachnoid cyst 17.27 13.10 5 17048 308 90611086
Drug effect less than expected 17.25 13.10 12 17041 6126 90605268
Pain of skin 17.13 13.10 18 17035 16064 90595330
Skin weeping 17.07 13.10 9 17044 2791 90608603
Wheezing 17.02 13.10 12 17041 238068 90373326
Tenosynovitis stenosans 16.73 13.10 10 17043 3943 90607451
Therapeutic response shortened 16.59 13.10 21 17032 22858 90588536
Arthrodesis 16.45 13.10 9 17044 3003 90608391
Rheumatoid arthritis 16.25 13.10 27 17026 362587 90248807
Tremor 15.91 13.10 64 16989 153109 90458285
Blood uric acid decreased 15.89 13.10 6 17047 847 90610547
Erythema 15.84 13.10 85 16968 229161 90382233
Discomfort 15.77 13.10 17 17036 274318 90337076
Bursitis 15.45 13.10 3 17050 131651 90479743
Therapeutic product ineffective 15.41 13.10 8 17045 2406 90608988
Pyrexia 15.37 13.10 68 16985 660417 89950977
Hypertrophy 15.08 13.10 5 17048 483 90610911
Fungal infection 15.02 13.10 28 17025 42633 90568761
Idiopathic intracranial hypertension 15.00 13.10 9 17044 3572 90607822
Rash macular 14.80 13.10 23 17030 30257 90581137
Stomatitis 14.73 13.10 18 17035 274680 90336714
Haematopoietic neoplasm 14.69 13.10 3 17050 41 90611353
Illness 14.53 13.10 41 17012 81928 90529466
Drug intolerance 14.50 13.10 40 17013 447551 90163843
Abdominal discomfort 14.48 13.10 44 17009 477284 90134110
Chest X-ray abnormal 14.43 13.10 10 17043 5072 90606322
Guttate psoriasis 14.14 13.10 5 17048 586 90610808
Irritable bowel syndrome 14.13 13.10 11 17042 207437 90403957
Dermatitis contact 14.09 13.10 15 17038 13580 90597814
Drug clearance increased 14.01 13.10 4 17049 234 90611160
Fibromyalgia 13.97 13.10 11 17042 206258 90405136
Adrenocortical carcinoma 13.76 13.10 3 17050 57 90611337
Bacterial test positive 13.66 13.10 10 17043 5529 90605865
Body tinea 13.37 13.10 7 17046 2141 90609253
Rosacea 13.17 13.10 10 17043 5837 90605557

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 98.83 13.40 208 14550 188563 42418014
Skin exfoliation 97.03 13.40 94 14664 41459 42565118
Seborrhoeic dermatitis 90.89 13.40 32 14726 2000 42604577
Psoriasis 68.03 13.40 84 14674 48520 42558057
Drug ineffective 64.25 13.40 404 14354 629793 41976784
Skin plaque 50.17 13.40 29 14729 5834 42600743
Dermatitis atopic 47.01 13.40 37 14721 12367 42594210
Rash 41.80 13.40 198 14560 276756 42329821
Dry skin 38.65 13.40 64 14694 48274 42558303
Erythema 38.42 13.40 103 14655 108690 42497887
Product use in unapproved indication 37.98 13.40 145 14613 184311 42422266
Dermatitis 35.76 13.40 31 14727 11844 42594733
Tinea cruris 34.40 13.40 11 14747 510 42606067
Eczema 32.60 13.40 49 14709 34037 42572540
Toxicity to various agents 31.90 13.40 20 14738 229116 42377461
Skin hyperpigmentation 31.37 13.40 19 14739 4162 42602415
Seborrhoeic keratosis 31.19 13.40 14 14744 1657 42604920
Skin papilloma 29.87 13.40 16 14742 2778 42603799
Melanocytic naevus 28.84 13.40 16 14742 2976 42603601
Therapeutic response unexpected 27.01 13.40 26 14732 11355 42595222
Papule 25.64 13.40 19 14739 5807 42600770
Product dose omission issue 25.17 13.40 113 14645 154252 42452325
Colour vision tests normal 25.10 13.40 4 14754 4 42606573
Scab 23.28 13.40 18 14740 5860 42600717
Prostatic specific antigen increased 23.25 13.40 29 14729 16896 42589681
Arthralgia 22.83 13.40 135 14623 205103 42401474
Macule 22.73 13.40 12 14746 2023 42604554
Leg amputation 22.51 13.40 13 14745 2610 42603967
Central vision loss 21.65 13.40 4 14754 15 42606562
Chemical burn 21.46 13.40 7 14751 346 42606231
Alcohol intolerance 21.10 13.40 7 14751 365 42606212
Pleocytosis 20.62 13.40 8 14750 657 42605920
Therapeutic product effect incomplete 20.02 13.40 62 14696 70877 42535700
Burning sensation 19.79 13.40 30 14728 20983 42585594
Anaplastic astrocytoma 19.56 13.40 5 14753 102 42606475
Hepatitis fulminant 19.23 13.40 15 14743 4944 42601633
Tinea versicolour 18.90 13.40 7 14751 506 42606071
Lentigo 18.86 13.40 8 14750 826 42605751
Herpes virus infection 18.44 13.40 13 14745 3679 42602898
Guttate psoriasis 18.23 13.40 7 14751 559 42606018
Drug ineffective for unapproved indication 17.59 13.40 45 14713 46118 42560459
Skin burning sensation 17.57 13.40 17 14741 7470 42599107
Puncture site haemorrhage 17.54 13.40 6 14752 344 42606233
Bone disorder 17.40 13.40 16 14742 6597 42599980
Actinic elastosis 16.74 13.40 4 14754 61 42606516
Vitamin E deficiency 16.08 13.40 3 14755 12 42606565
Skin lesion 15.39 13.40 31 14727 27143 42579434
Blood testosterone decreased 15.17 13.40 13 14745 4889 42601688
Product administration interrupted 15.02 13.40 13 14745 4953 42601624
Nosocomial infection 14.72 13.40 8 14750 1428 42605149
Adrenal suppression 14.63 13.40 7 14751 958 42605619
Tinea pedis 14.58 13.40 9 14749 2039 42604538
Coccydynia 13.95 13.40 6 14752 641 42605936
Achromotrichia acquired 13.72 13.40 3 14755 30 42606547
Adrenal insufficiency 13.72 13.40 24 14734 18900 42587677
Polyarteritis nodosa 13.67 13.40 5 14753 349 42606228
Psoriatic arthropathy 13.56 13.40 28 14730 24939 42581638

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 154.42 11.84 168 23093 139825 110426213
Dermatitis atopic 115.17 11.84 70 23191 25471 110540567
Dry skin 78.87 11.84 105 23156 107548 110458490
Product dose omission issue 75.16 11.84 191 23070 321591 110244447
Pruritus 74.74 11.84 280 22981 581280 109984758
Seborrhoeic dermatitis 73.94 11.84 26 23235 2681 110563357
Eczema 69.79 11.84 81 23180 72212 110493826
Swelling of eyelid 69.57 11.84 32 23229 6621 110559417
Endocrine ophthalmopathy 65.05 11.84 20 23241 1353 110564685
Skin exfoliation 61.92 11.84 84 23177 87567 110478471
Nasal ulcer 59.95 11.84 22 23239 2565 110563473
Toxic shock syndrome 54.88 11.84 18 23243 1502 110564536
Eyelid disorder 54.06 11.84 20 23241 2385 110563653
Drug ineffective for unapproved indication 53.04 11.84 85 23176 102753 110463285
Cortisol increased 51.29 11.84 14 23247 620 110565418
Adrenal insufficiency 43.44 11.84 49 23212 42341 110523697
Infusion related reaction 40.12 11.84 15 23246 381147 110184891
Toxicity to various agents 39.90 11.84 26 23235 480529 110085509
Completed suicide 39.53 11.84 3 23258 242378 110323660
Dermatitis 38.95 11.84 38 23223 27799 110538239
Impetigo 35.40 11.84 15 23246 2553 110563485
Mean cell haemoglobin increased 34.96 11.84 19 23242 5598 110560440
Vitamin D decreased 34.46 11.84 25 23236 12190 110553848
Product administration interrupted 31.61 11.84 23 23238 11269 110554769
Contraindicated product administered 31.20 11.84 7 23254 248260 110317778
Glossodynia 30.56 11.84 5 23256 221999 110344039
Intertrigo 30.44 11.84 11 23250 1227 110564811
Tarsal tunnel syndrome 30.32 11.84 9 23252 540 110565498
Drug interaction 30.09 11.84 194 23067 499989 110066049
Purpura senile 29.31 11.84 9 23252 606 110565432
Wound 28.68 11.84 7 23254 234430 110331608
Drug intolerance 28.63 11.84 26 23235 406486 110159552
Rhabdomyolysis 28.60 11.84 72 23189 120329 110445709
Hypothalamic pituitary adrenal axis suppression 28.40 11.84 9 23252 673 110565365
General physical health deterioration 27.87 11.84 29 23232 425266 110140772
Helicobacter infection 27.65 11.84 3 23258 181874 110384164
Rash 27.30 11.84 278 22983 820686 109745352
Colour vision tests normal 27.10 11.84 4 23257 4 110566034
Therapeutic response unexpected 26.92 11.84 29 23232 23814 110542224
Systemic lupus erythematosus 26.77 11.84 10 23251 254328 110311710
Dyslipidaemia 26.57 11.84 24 23237 15941 110550097
Lower respiratory tract infection 26.54 11.84 9 23252 243097 110322941
Drug ineffective 25.98 11.84 456 22805 1520084 109045954
Skin disorder 25.67 11.84 38 23223 42875 110523163
Therapeutic response shortened 25.02 11.84 31 23230 29552 110536486
Eye infection 24.51 11.84 22 23239 14496 110551542
Drug abuse 24.41 11.84 4 23257 177407 110388631
Skin laceration 23.30 11.84 32 23229 33721 110532317
Leg amputation 22.79 11.84 13 23248 4205 110561833
Pelvic pain 22.75 11.84 22 23239 15920 110550118
Flatulence 22.74 11.84 40 23221 52109 110513929
Synovial cyst 22.69 11.84 19 23242 11411 110554627
Vestibular disorder 22.44 11.84 11 23250 2621 110563417
Hepatotoxicity 21.88 11.84 44 23217 63356 110502682
Injection site pain 21.39 11.84 84 23177 177838 110388200
Resorption bone increased 21.28 11.84 9 23252 1525 110564513
Vertigo positional 20.88 11.84 12 23249 3936 110562102
Hepatitis fulminant 20.76 11.84 16 23245 8544 110557494
Anaplastic astrocytoma 20.26 11.84 5 23256 148 110565890
Chemical burn 19.73 11.84 7 23254 741 110565297
Tremor 19.29 11.84 89 23172 202143 110363895
Folliculitis 18.66 11.84 6 23255 167647 110398391
Skin ulcer 18.29 11.84 41 23220 63604 110502434
Central vision loss 18.21 11.84 4 23257 70 110565968
Bursitis 17.71 11.84 3 23258 129915 110436123
Cortisol free urine decreased 17.58 11.84 3 23258 12 110566026
Aspergillus test positive 17.42 11.84 7 23254 1043 110564995
Hyperadrenocorticism 17.27 11.84 6 23255 597 110565441
Skin swelling 17.23 11.84 14 23247 8066 110557972
Impaired healing 17.20 11.84 10 23251 196707 110369331
Pleocytosis 17.12 11.84 8 23253 1716 110564322
Pneumonia mycoplasmal 17.04 11.84 8 23253 1733 110564305
Skin papilloma 16.96 11.84 13 23248 6883 110559155
Erythema 16.86 11.84 112 23149 291335 110274703
Tenosynovitis stenosans 16.56 11.84 10 23251 3593 110562445
Deafness bilateral 16.42 11.84 9 23252 2695 110563343
Herpes virus infection 16.41 11.84 14 23247 8624 110557414
Arthrodesis 16.38 11.84 9 23252 2709 110563329
Myalgia 16.38 11.84 91 23170 222290 110343748
Headache 16.21 11.84 268 22993 882109 109683929
Puncture site haemorrhage 16.13 11.84 6 23255 726 110565312
Fibromyalgia 15.94 11.84 8 23253 170901 110395137
Dermatitis contact 15.80 11.84 17 23244 13936 110552102
Synovitis 15.47 11.84 21 23240 274071 110291967
Skin plaque 15.37 11.84 16 23245 12629 110553409
Product use in unapproved indication 15.06 11.84 152 23109 447225 110118813
Nosocomial infection 15.02 11.84 9 23252 3190 110562848
Alcohol intolerance 14.96 11.84 5 23256 442 110565596
Arachnoid cyst 14.93 11.84 5 23256 445 110565593
Vitamin E deficiency 14.87 11.84 3 23258 34 110566004
Feeding disorder 14.36 11.84 20 23241 21342 110544696
No adverse event 14.35 11.84 41 23220 73798 110492240
Swelling 14.30 11.84 33 23228 351008 110215030
Joint range of motion decreased 14.21 11.84 4 23257 121828 110444210
Liver injury 14.09 11.84 7 23254 150406 110415632
Rheumatoid arthritis 14.03 11.84 26 23235 299587 110266451
Guttate psoriasis 13.94 11.84 5 23256 546 110565492
Dermatitis psoriasiform 13.94 11.84 9 23252 3635 110562403
Rash macular 13.53 11.84 27 23234 38659 110527379
Irritable bowel syndrome 13.45 11.84 9 23252 164206 110401832
Polyarteritis nodosa 13.25 11.84 5 23256 630 110565408
Application site pain 12.73 11.84 10 23251 5489 110560549
Transient aphasia 12.71 11.84 5 23256 704 110565334
Muscle spasms 12.69 11.84 101 23160 278056 110287982
Mobility decreased 12.60 11.84 19 23242 237403 110328635
Skin burning sensation 12.58 11.84 19 23242 21806 110544232
Off label use 12.57 11.84 408 22853 1499777 109066261
Hepatic enzyme increased 12.40 11.84 31 23230 320861 110245177
Skin hyperpigmentation 12.40 11.84 12 23249 8684 110557354
Penile oedema 12.38 11.84 4 23257 318 110565720
Adrenocortical insufficiency acute 12.33 11.84 9 23252 4431 110561607
Surgery 12.32 11.84 27 23234 41256 110524782
Lung consolidation 12.28 11.84 13 23248 10463 110555575
Post inflammatory pigmentation change 12.27 11.84 5 23256 772 110565266
Fungal skin infection 12.26 11.84 11 23250 7238 110558800
Swelling face 12.25 11.84 45 23216 92276 110473762
Stomatitis 12.17 11.84 24 23237 270218 110295820
Skin candida 12.11 11.84 7 23254 2321 110563717
Haematopoietic neoplasm 12.02 11.84 3 23258 93 110565945
Blood uric acid decreased 12.02 11.84 6 23255 1487 110564551
Cryptococcosis 11.99 11.84 9 23252 4622 110561416
Adrenocortical carcinoma 11.96 11.84 3 23258 95 110565943
Drug hypersensitivity 11.94 11.84 52 23209 454038 110112000
Erectile dysfunction 11.92 11.84 17 23244 18539 110547499

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AC08 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC G01AF11 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
ATC H02CA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
CORTICOSTEROIDS FOR SYSTEMIC USE
ANTIADRENAL PREPARATIONS
Anticorticosteroids
ATC J02AB02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Imidazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D065088 Steroid Synthesis Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190115 Cytochrome P450 3A5 Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:50864 insulin-sensitizing drug
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:55324 gastrointestinal drug
CHEBI has role CHEBI:65023 anti-asthmatic agent

Related Drugs by ATC class:

D01AC Imidazole and triazole derivatives 20 drugs
bifonazolechlormidazoleclotrimazoleeberconazoleeconazoleefinaconazolefenticonazolefluconazoleflutrimazoleisoconazolelanoconazoleluliconazole show all 20 →
G01AF Imidazole derivatives 16 drugs
azanidazolebutoconazoleclotrimazoleeconazolefenticonazoleflutrimazoleisoconazolemetronidazolemiconazoleomoconazoleornidazoleoxiconazole show all 16 →
H02CA Anticorticosteroids 2 drugs
osilodrostattrilostane
J02AB Imidazole derivatives 1 drug
miconazole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Histoplasmosis indication 12962009 DOID:1731
Hypercortisolism indication 47270006
Candidiasis of skin indication 49883006
Seborrheic dermatitis indication 50563003 DOID:8741
Pityriasis versicolor indication 56454009 DOID:9060
Paracoccidioidomycosis indication 59925007 DOID:12662
Coccidioidomycosis indication 60826002 DOID:13450
Blastomycosis indication 69996000 DOID:12663
Disseminated candidiasis indication 70572005
Candidiasis of mouth indication 79740000 DOID:14262
Tinea corporis indication 84849002
Chromoblastomycosis indication 187079000
Pityriasis simplex indication 200767005
Tinea cruris indication 399029005
Paronychia off-label use 71906005 DOID:13117
Advanced Prostatic Carcinoma off-label use
Torsades de pointes contraindication 31722008
Achlorhydria contraindication 47481007
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.84 Basic
pKa2 3.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Steroid 17-alpha-hydroxylase/17,20 lyase Enzyme INHIBITOR IC50 7.28 WOMBAT-PK DRUG LABEL
Cytochrome P450 11B1, mitochondrial Enzyme INHIBITOR IC50 6.90 SCIENTIFIC LITERATURE DRUG LABEL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.72 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 7 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 6 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 6.55 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 4.62 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.08 DRUG MATRIX
Histamine H2 receptor GPCR Ki 4.67 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.03 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.46 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 4.73 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 4.84 DRUG MATRIX
ATP-binding cassette sub-family G member 2 Transporter IC50 4.82 CHEMBL
Cytochrome P450 2C8 Enzyme IC50 5.81 CHEMBL
Delta-type opioid receptor GPCR Ki 5.35 DRUG MATRIX
Bile salt export pump Transporter IC50 5.54 CHEMBL
Cytochrome P450 2C9 Enzyme IC50 4.40 CHEMBL
Aromatase Enzyme Ki 6.40 CHEMBL
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Enzyme IC50 6.47 CHEMBL
Potassium voltage-gated channel subfamily A member 10 Ion channel BLOCKER IC50 6.30 IUPHAR
Cytochrome P450 2C19 Enzyme IC50 4.72 CHEMBL
Thromboxane-A synthase Enzyme IC50 5.67 DRUG MATRIX
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.60 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.58 CHEMBL
Substance-K receptor GPCR Ki 5.24 DRUG MATRIX
Cytochrome P450 3A5 Enzyme IC50 6.92 CHEMBL
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Enzyme IC50 6.51 WOMBAT-PK
Cytochrome P450 21 Enzyme IC50 5.05 CHEMBL
Lanosterol 14-alpha demethylase Enzyme app Ki 7.20 WOMBAT-PK
Cytochrome P450 26A1 Enzyme IC50 6.18 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 5.66 CHEMBL
Cytochrome P450 11B2, mitochondrial Enzyme INHIBITOR IC50 7.17 SCIENTIFIC LITERATURE
Sodium/nucleoside cotransporter 1 Transporter Ki 5.82 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.13 DRUG MATRIX
Lanosterol 14-alpha demethylase Enzyme INHIBITOR IC50 7 WOMBAT-PK CHEMBL
Heme oxygenase 2 Enzyme IC50 5.16 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.27 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 4.90 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.21 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.01 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 4.45 CHEMBL
Gonadotropin-releasing hormone receptor GPCR Kd 9.66 CHEMBL
Cytochrome P450 11B1 Enzyme IC50 6.82 CHEMBL
Cytochrome P450 11A1 Enzyme IC50 5.91 CHEMBL
Cytochrome P450 24A1 Enzyme IC50 4.70 CHEMBL
Cytochrome P450 7A1 Enzyme IC50 6.71 CHEMBL
Cytochrome P450 51 Enzyme Ki 7.19 CHEMBL
Cytochrome P450 17A1 Enzyme IC50 6.69 CHEMBL
Bile salt export pump Transporter IC50 4.81 CHEMBL
Heme oxygenase 1 Enzyme IC50 6.52 CHEMBL
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Enzyme IC50 6.44 CHEMBL

External reference:

IDSource
4019271 VUID
N0000147470 NUI
D00351 KEGG_DRUG
4019271 VANDF
C0022625 UMLSCUI
CHEBI:47519 CHEBI
KTN PDB_CHEM_ID
CHEMBL157101 ChEMBL_ID
D007654 MESH_DESCRIPTOR_UI
DB01026 DRUGBANK_ID
2568 IUPHAR_LIGAND_ID
4594 INN_ID
R9400W927I UNII
47576 PUBCHEM_CID
202692 RXNORM
2701 MMSL
31001 MMSL
4945 MMSL
d00103 MMSL
002903 NDDF
387216007 SNOMEDCT_US
40232005 SNOMEDCT_US
R9400W927I INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-3219 CREAM 20 mg TOPICAL ANDA 17 sections
ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 0168-0099 CREAM 20 mg TOPICAL ANDA 16 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 0713-0592 SHAMPOO, SUSPENSION 20 mg TOPICAL ANDA 16 sections
KETOCONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16590-998 TABLET 200 mg ORAL ANDA 22 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-955 CREAM 20 mg TOPICAL ANDA 18 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 21695-554 CREAM 20 mg TOPICAL ANDA 19 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 21695-555 CREAM 20 mg TOPICAL ANDA 19 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 21695-556 CREAM 20 mg TOPICAL ANDA 19 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 21695-562 TABLET 200 mg ORAL ANDA 23 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 21922-025 CREAM 20 mg TOPICAL ANDA 15 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 33261-739 TABLET 200 mg ORAL ANDA 26 sections
KETOCONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 35573-433 TABLET 200 mg ORAL ANDA 15 sections
Ketodan HUMAN PRESCRIPTION DRUG LABEL 1 43538-530 AEROSOL, FOAM 20 mg TOPICAL ANDA 31 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 45802-465 SHAMPOO, SUSPENSION 20 mg TOPICAL ANDA 17 sections
ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 45802-532 AEROSOL, FOAM 2 g TOPICAL ANDA 27 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-1220 SHAMPOO, SUSPENSION 20 mg TOPICAL ANDA 18 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-1524 CREAM 20 mg TOPICAL ANDA 18 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-1675 CREAM 20 mg TOPICAL ANDA 18 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-1992 TABLET 200 mg ORAL ANDA 26 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-3288 SHAMPOO, SUSPENSION 20 mg TOPICAL ANDA 17 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-5265 CREAM 20 mg TOPICAL ANDA 17 sections
Ketoconazole Human Prescription Drug Label 1 50090-6046 CREAM 20 mg TOPICAL ANDA 15 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-6069 CREAM 20 mg TOPICAL ANDA 17 sections
KETOCONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50090-6142 TABLET 200 mg ORAL ANDA 15 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 50090-7538 SHAMPOO, SUSPENSION 20 mg TOPICAL ANDA 16 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 51407-279 CREAM 20 mg TOPICAL ANDA 19 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 51672-1298 CREAM 20 mg TOPICAL ANDA 19 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 51672-4026 TABLET 200 mg ORAL ANDA 26 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 53002-8150 CREAM 20 mg TOPICAL ANDA 18 sections
Ketoconazole HUMAN PRESCRIPTION DRUG LABEL 1 53002-8151 CREAM 20 mg TOPICAL ANDA 17 sections